{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T11:29:45Z","timestamp":1793791785023,"version":"4.6.1"},"reference-count":20,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2026.0154","type":"journal-article","created":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T11:05:53Z","timestamp":1793790353000},"source":"Crossref","is-referenced-by-count":0,"title":["Antibiotic treatment of severe infections with multiresistant bacteria"],"prefix":"10.3238","author":[{"given":"S\u00f6ren G.","family":"Gatermann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Ewig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Grabein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Vehreschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias W.","family":"Pletz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2026,11,13]]},"reference":[{"key":"10.3238\/arztebl.m2026.0154_ref1","doi-asserted-by":"crossref","unstructured":"Cassini A, H\u00f6gberg LD, Plachouras D, et al.: Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: A population-level modelling analysis. Lancet Infect Dis 2019; 19: 56\u201366.","DOI":"10.1016\/S1473-3099(18)30605-4"},{"key":"10.3238\/arztebl.m2026.0154_ref2","doi-asserted-by":"crossref","unstructured":"Eckmanns T, Reichert F, Schneider M, Feig M, Noll I, Hoffmann A: Entwicklung der Epidemiologie antibiotikaresistenter Erreger in der Humanmedizin und deren Bedeutung f\u00fcr das Gesundheitssystem. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2026; 69: 546\u201355.","DOI":"10.1007\/s00103-026-04234-6"},{"key":"10.3238\/arztebl.m2026.0154_ref3","doi-asserted-by":"crossref","unstructured":"Wilke MH, Preisend\u00f6rfer B, Seiffert A, Kleppisch M, Schweizer C, Rauchensteiner S: Carbapenem-resistant gram-negative bacteria in Germany: Incidence and distribution among specific infections and mortality: An epidemiological analysis using real-world data. Infection 2022; 50: 1535\u201342.","DOI":"10.1007\/s15010-022-01843-6"},{"key":"10.3238\/arztebl.m2026.0154_ref4","unstructured":"World Health Organisation: WHO Bacterial Priority Pathogens List 2024: Bacterial Pathogens of Public Health Importance, to Guide Research, Development, and Strategies to Prevent and Control Antimicrobial Resistance. 1st edition Geneva: World Health Organization; 2024."},{"key":"10.3238\/arztebl.m2026.0154_ref5","unstructured":"Deutsche Gesellschaft f\u00fcr Hygiene und Mikrobiologie e.V. (eds.): Antibiotikatherapie schwerer Infektionen mit multiresistenten Bakterien. S3-Leitlinie. 2025. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/067\u2013011 (last accessed on 4 September 2026)."},{"key":"10.3238\/arztebl.m2026.0154_ref6","unstructured":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF): AWMF-Regelwerk Leitlinien, Version 2.1 vom 05.09.2023. www.awmf.org\/regelwerk (last accessed on 26 April 2026)."},{"key":"10.3238\/arztebl.m2026.0154_ref7","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). Cefiderocol: EUCAST warning concerning commercially available tests.www.eucast.org\/about-eucast\/warnings\/ (last accessed on 4 September 2026)."},{"key":"10.3238\/arztebl.m2026.0154_ref8","unstructured":"EUCAST: Recommendations for MIC determination of colistin. Im Internet: www.eucast.org\/fileadmin\/eucast\/pdf\/guidance_documents\/Recommendations_for_MIC_determination_of_colistin_March_2016.pdf (last accessed on 26 April 2026)."},{"key":"10.3238\/arztebl.m2026.0154_ref9","unstructured":"Pfennigwerth N, M\u00f6ller S, Eisfeld J, Pankok F, Gatermann S: Bericht des Nationalen Referenzzentrums f\u00fcr gramnegative Krankenhauserreger f\u00fcr das Jahr 2024. Epid Bull 2025; 20\/21: 3. doi:10.25646\/13143."},{"key":"10.3238\/arztebl.m2026.0154_ref10","doi-asserted-by":"crossref","unstructured":"Karampatakis T, Tsergouli K, Lowrie K: Efficacy and safety of ceftazidime-avibactam compared to other antimicrobials for the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae strains, a systematic review and meta-analysis. Microb Pathog 2023; 179: 106090.","DOI":"10.1016\/j.micpath.2023.106090"},{"key":"10.3238\/arztebl.m2026.0154_ref11","doi-asserted-by":"crossref","unstructured":"Motsch J, Murta de Oliveira C, Stus V, et al.: RESTORE-IMI 1: A multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections. Clin Infect Dis 2020; 70: 1799\u2013808.","DOI":"10.1093\/cid\/ciz530"},{"key":"10.3238\/arztebl.m2026.0154_ref12","doi-asserted-by":"crossref","unstructured":"Karakonstantis S, Kritsotakis EI, Tziolos RN, et al.: Mortality due to carbapenem-resistant Acinetobacter baumannii bacteraemia: A 5-year cohort study in intensive care patients. Clin Microbiol Infect 2025; 31: 1033\u20139.","DOI":"10.1016\/j.cmi.2025.02.018"},{"key":"10.3238\/arztebl.m2026.0154_ref13","doi-asserted-by":"crossref","unstructured":"Kaye KS, Shorr AF, Wunderink RG, et al.: Efficacy and safety of sulbactamdurlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: A multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK). Lancet Infect Dis 2023; 23: 1072\u201384.","DOI":"10.1016\/S1473-3099(23)00184-6"},{"key":"10.3238\/arztebl.m2026.0154_ref14","doi-asserted-by":"crossref","unstructured":"Maraolo AE, Giaccone A, Gentile I, Saracino A, Bavaro DF: Daptomycin versus Vancomycin for the treatment of methicillin-resistant staphylococcus aureus bloodstream infection with or without endocarditis: A systematic review and meta-analysis. Antibiotics (Basel) 2021; 10: 1014.","DOI":"10.3390\/antibiotics10081014"},{"key":"10.3238\/arztebl.m2026.0154_ref15","doi-asserted-by":"crossref","unstructured":"Kawasuji H, Nagaoka K, Tsuji Y, et al.: Effectiveness and safety of linezolid versus vancomycin, teicoplanin, or daptomycin against methicillin-resistant staphylococcus aureus bacteremia: A systematic review and meta-analysis. Antibiotics (Basel) 2023; 12: 697.","DOI":"10.3390\/antibiotics12040697"},{"key":"10.3238\/arztebl.m2026.0154_ref16","doi-asserted-by":"crossref","unstructured":"Holland TL, Cosgrove SE, Doernberg SB, et al.: Ceftobiprole for treatment of complicated staphylococcus aureus bacteremia. N Engl J Med 2023; 389: 1390\u2013401.","DOI":"10.1056\/NEJMoa2300220"},{"key":"10.3238\/arztebl.m2026.0154_ref17","doi-asserted-by":"crossref","unstructured":"Mart\u00ed-Carvajal AJ, Dayer M, Conterno LO, Gonzalez Garay AG, Mart\u00ed-Amarista CE: A comparison of different antibiotic regimens for the treatment of infective endocarditis. Cochrane Database Syst Rev 2020; 5: CD009880.","DOI":"10.1002\/14651858.CD009880.pub3"},{"key":"10.3238\/arztebl.m2026.0154_ref18","doi-asserted-by":"crossref","unstructured":"Zhang Y, Wang Y, Van Driel ML, et al.: Network meta-analysis and pharmacoeconomic evaluation of antibiotics for the treatment of patients infected with complicated skin and soft structure infection and hospital-acquired or ventilator-associated pneumonia. Antimicrob Resist Infect Control 2019; 8: 72.","DOI":"10.1186\/s13756-019-0518-2"},{"key":"10.3238\/arztebl.m2026.0154_ref19","doi-asserted-by":"crossref","unstructured":"Shi C, Jin W, Xie Y, et al.: Efficacy and safety of daptomycin versus linezolid treatment in patients with vancomycin-resistant enterococcal bacteraemia: An updated systematic review and meta-analysis. J Glob Antimicrob Resist 2020; 21: 235\u201345.","DOI":"10.1016\/j.jgar.2019.10.008"},{"key":"10.3238\/arztebl.m2026.0154_ref20","doi-asserted-by":"crossref","unstructured":"Chuang YC, Lin HY, Wang JT, et al.: Daptomycin area under the curve to minimum inhibitory concentration ratio by broth microdilution for predicting the outcome of vancomycin-resistant Enterococcus bloodstream infection. Biomed Pharmacother 2022; 155: 113710.","DOI":"10.1016\/j.biopha.2022.113710"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2026.0154","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T11:06:06Z","timestamp":1793790366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2026.0154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11,13]]},"references-count":20,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2026.0154","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,11,13]]}}}